Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Jean-Pierre Llanos,1 Christopher F Bell,1 Elizabeth Packnett,2 Ellen Thiel,2 Debra E Irwin,2 Beth Hahn,1 Hector Ortega3 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Truven Health Analytics, An IBM Watson Health Company, Ann Arbor, MI, USA; 3Respiratory, US Medical Affairs...

Full description

Bibliographic Details
Main Authors: Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H
Format: Article
Language:English
Published: Dove Medical Press 2019-01-01
Series:Journal of Asthma and Allergy
Subjects:
asthma
mepolizumab
biologic
healthcare resource utilization
healthcare costs
Online Access:https://www.dovepress.com/real-world-characteristics-and-disease-burden-of-patients-with-asthma--peer-reviewed-article-JAA

Internet

https://www.dovepress.com/real-world-characteristics-and-disease-burden-of-patients-with-asthma--peer-reviewed-article-JAA

Similar Items